OA07069A - Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation. - Google Patents

Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation.

Info

Publication number
OA07069A
OA07069A OA57657A OA57657A OA07069A OA 07069 A OA07069 A OA 07069A OA 57657 A OA57657 A OA 57657A OA 57657 A OA57657 A OA 57657A OA 07069 A OA07069 A OA 07069A
Authority
OA
OAPI
Prior art keywords
ricin
preparation
cancer drugs
drugs containing
chain associated
Prior art date
Application number
OA57657A
Other languages
English (en)
French (fr)
Inventor
Jansen Franz Klauss
Gros Pierre
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of OA07069A publication Critical patent/OA07069A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
OA57657A 1981-04-15 1982-04-13 Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation. OA07069A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8107596A FR2504010B1 (fr) 1981-04-15 1981-04-15 Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation

Publications (1)

Publication Number Publication Date
OA07069A true OA07069A (fr) 1984-01-31

Family

ID=9257448

Family Applications (1)

Application Number Title Priority Date Filing Date
OA57657A OA07069A (fr) 1981-04-15 1982-04-13 Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation.

Country Status (30)

Country Link
US (1) US4414148A (es)
EP (1) EP0063988B1 (es)
JP (1) JPS57179124A (es)
KR (1) KR880001045B1 (es)
AR (1) AR228394A1 (es)
AT (1) ATE17653T1 (es)
AU (1) AU556641B2 (es)
CA (1) CA1195248A (es)
CZ (1) CZ256482A3 (es)
DD (1) DD204849A5 (es)
DE (1) DE3268752D1 (es)
DK (1) DK159277C (es)
EG (1) EG15718A (es)
ES (1) ES511433A0 (es)
FI (1) FI76693C (es)
FR (1) FR2504010B1 (es)
GR (1) GR69199B (es)
HU (1) HU188314B (es)
IE (1) IE53009B1 (es)
IL (1) IL65441A0 (es)
MA (1) MA19429A1 (es)
NO (1) NO154905C (es)
NZ (1) NZ200302A (es)
OA (1) OA07069A (es)
PH (1) PH20846A (es)
PL (1) PL135800B1 (es)
PT (1) PT74741B (es)
SU (1) SU1329604A3 (es)
YU (1) YU83082A (es)
ZA (1) ZA822528B (es)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
DE3369466D1 (en) * 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
JPS5990052A (ja) * 1982-11-16 1984-05-24 Katsu Taniguchi モノクロ−ナル特異抗体を用いたメラノ−マ診断薬
US4916213A (en) * 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
US4591572A (en) * 1983-04-01 1986-05-27 Sloan-Kettering Institute For Cancer Research Pigmentation associated, differentiation antigen of human melanoma and autologous antibody
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
GB2142428A (en) * 1983-06-23 1985-01-16 Erba Farmitalia Adenocarcinoma related antigenic determinants and antibodies specific thereto
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
FR2570278B1 (fr) * 1984-09-14 1987-02-13 Pasteur Institut Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
EP0232447A1 (en) * 1986-02-13 1987-08-19 Xoma Corporation Lectin immunotoxins
AU585940B2 (en) * 1984-09-25 1989-06-29 Xoma Corporation Lectin immunotoxins
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
US4851510A (en) * 1984-11-30 1989-07-25 Wadley Technologies, Inc. Monoclonal antibodies to novel melanoma-associated antigens
US5256413A (en) * 1985-01-08 1993-10-26 The General Hospital Corporation Method and use for site-specific activation of substances
AT384549B (de) * 1985-01-08 1987-11-25 Strasser Engelbert Verfahren zur herstellung einer vaccine
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
WO1987003286A1 (en) * 1985-11-29 1987-06-04 The University Of Melbourne Ricin-antibody conjugates
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
US4689401A (en) * 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5009995A (en) * 1986-10-27 1991-04-23 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to melanoma cells
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
IE910820A1 (en) * 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
IL97776A (en) * 1990-04-19 2000-10-31 Res Dev Foundation Composition comprising a conjugate of a ZME antibody and a biological response modifier
US5981194A (en) * 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
US5690935A (en) * 1995-01-13 1997-11-25 Regents Of The University Of Minnesota Biotherapy of cancer by targeting TP-3/P80
ATE483733T1 (de) 1995-06-14 2010-10-15 Univ California Hochaffine humane antikörper gegen tumorantigene
WO1998012329A2 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US6869604B1 (en) * 1998-03-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant anti-tumor RNAse
ATE423570T1 (de) * 1998-05-08 2009-03-15 Univ California Verfahren zum nachweis und hemmung der angiogenese
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US20020155507A1 (en) 2000-10-06 2002-10-24 Bruchez Marcel P. Cells having a spectral signature, and methods of preparation and use thereof
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
EP2381116A1 (en) 2000-11-16 2011-10-26 California Institute of Technology Apparatus and methods for conducting assays and high throughput screening
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1406493A4 (en) * 2001-06-11 2006-06-14 Xenoport Inc ADMINISTRATION OF MEDIUM BY THE PEPT-2 TRANSPORTER
EP1414471B1 (en) * 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
WO2003048295A1 (en) 2001-11-30 2003-06-12 Fluidigm Corporation Microfluidic device and methods of using same
US20030158089A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Administrative agents via the SMVT transporter
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20030228619A1 (en) * 2002-06-10 2003-12-11 Xenoport, Inc. Peptide nucleic acids as tags in encoded libraries
EP1572170A4 (en) * 2002-06-12 2007-02-28 Res Dev Foundation IMMUNOTOXIN AS THERAPEUTIC AGENT AND USES THEREOF
DK1530482T3 (da) 2002-07-18 2014-01-20 Helix Biopharma Corp Brug af urease til at hæmme vækst af cancerceller
US20040161424A1 (en) * 2002-10-08 2004-08-19 Xenoport Human organic solute transporters
EP1615721B1 (en) 2003-04-03 2014-06-18 Fluidigm Corporation Microfluidic devices and methods of using same
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
AU2005306576A1 (en) * 2004-11-16 2006-05-26 Sienna Cancer Diagnostics Ltd Methods of detecting an analyte in a sample
CN102732588B (zh) * 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
CN103290084A (zh) 2004-12-22 2013-09-11 Ambrx公司 表达和纯化重组人类生长激素的方法
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
CN103690936A (zh) 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
SG161209A1 (en) * 2004-12-22 2010-05-27 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
CA2595904A1 (en) * 2005-02-01 2006-08-10 Research Development Foundation Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
EP2371453A1 (en) 2005-03-18 2011-10-05 Fluidigm Corporation Microfluidic device
KR20080026135A (ko) * 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
WO2007021297A1 (en) * 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
AU2006311568B2 (en) * 2005-11-08 2010-11-11 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
JP2009520949A (ja) * 2005-11-16 2009-05-28 アンブルックス，インコーポレイテッド 非天然アミノ酸を含んでいる組成物および方法
US20080317670A1 (en) * 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
CN106008699A (zh) * 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
ES2457527T3 (es) * 2006-09-08 2014-04-28 Ambrx, Inc. ARNt Supresor hibrido en células de vertebrados
CA2662755C (en) * 2006-09-08 2017-04-04 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
JP5650406B2 (ja) 2007-03-07 2015-01-07 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
CA2682147C (en) * 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2008137471A2 (en) * 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2192922A4 (en) 2007-09-17 2010-09-29 Univ California INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGING PROSTATE <I> IN SITU CANCER CELLS </ I>
EP3150218B1 (en) 2007-09-21 2021-09-08 The Regents Of The University Of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
IL198123A0 (en) 2008-04-18 2009-12-24 Snecma Propulsion Solide A heat treatment oven with inductive heating
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
CA2738033C (en) 2008-09-26 2019-11-26 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
AU2010210600B2 (en) 2009-02-06 2016-07-14 C3 Jian, Inc. Calcium-binding agents induce hair growth and/or nail growth
CN102666578A (zh) 2009-12-21 2012-09-12 Ambrx公司 经过修饰的猪促生长素多肽和其用途
PE20121707A1 (es) 2009-12-21 2012-12-17 Ambrx Inc Polipeptidos de somatotropina bovina modificados y sus usos
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
RS59193B1 (sr) 2010-08-17 2019-10-31 Ambrx Inc Modifikovani polipeptidi relaksina i njihova primena
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
AU2011302645B2 (en) 2010-09-15 2015-02-26 Applied Molecular Transport, Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
MX362653B (es) 2010-09-29 2019-01-30 Uti Lp Composiciones de alta densidad de partícula que comprenden complejos de nanoesferas bioabsorbibles biocompatibles y sus usos.
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CN103518135B (zh) 2011-03-11 2016-08-17 内布拉斯加大学董事委员会 冠状动脉疾病的生物标志物
EP2694095B1 (en) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
EP3470413A3 (en) 2011-05-27 2019-08-07 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
LT2822575T (lt) 2012-03-03 2020-06-25 Immungene, Inc. Sukonstruotos antikūno-mutantinio interferono sulietos molekulės
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
EP2858676B1 (en) 2012-06-07 2019-03-13 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
CN104619350A (zh) 2012-06-14 2015-05-13 Ambrx公司 结合到核受体配体多肽的抗psma抗体
MX359449B (es) 2012-06-19 2018-09-28 Ambrx Inc Conjugados de anticuerpo fármaco anti-cd70.
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP2968469A4 (en) 2013-03-15 2016-08-31 Longevity Biotech Inc PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
TR201908418T4 (tr) 2013-11-04 2019-07-22 Uti Lp Sürdürülebilir immünoterapi için yöntem ve kompozisyonlar.
FR3018526B1 (fr) 2014-03-14 2021-06-11 Herakles Installation de densification cvi comprenant une zone de prechauffage a forte capacite
EP3139965B1 (en) 2014-05-07 2021-09-29 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
TW202124419A (zh) 2014-10-24 2021-07-01 美商必治妥美雅史谷比公司 經修飾之fgf-21多肽及其用途
KR20180011135A (ko) 2015-05-06 2018-01-31 유티아이 리미티드 파트너쉽 지속 치료를 위한 나노입자 조성물
KR20180077271A (ko) 2015-11-03 2018-07-06 암브룩스, 인코포레이티드 항-ｃｄ3-폴레이트 컨쥬게이트 및 이의 용도
WO2017095823A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
EP3442996A4 (en) 2016-04-12 2019-11-27 Blaze Bioscience, Inc. METHODS OF TREATMENT INVOLVING CHLOROTOXIN CONJUGATES
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
WO2018089807A2 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
ES2928184T3 (es) 2016-12-12 2022-11-16 Cepheid Inmuno-PCR integrado y análisis de ácidos nucleicos en un cartucho de reacción automatizado
CA3049212A1 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
WO2018148419A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
ES2920428T3 (es) 2018-03-08 2022-08-03 Applied Molecular Transport Inc Constructos de administración derivados de toxinas para la administración oral
PT3762009T (pt) 2018-03-08 2022-08-22 Applied Molecular Transport Inc Construções de administração derivadas de toxinas para administração oral
WO2019191728A1 (en) 2018-03-29 2019-10-03 Ambrx, Inc. Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
AU2019327456A1 (en) 2018-08-28 2021-04-15 Ambrx, Inc. anti-CD3 antibody folate bioconjugates and their uses
AU2019337610A1 (en) 2018-09-11 2021-05-06 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
MX2021009644A (es) 2019-02-12 2021-09-08 Ambrx Inc Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
KR20220066056A (ko) 2019-08-16 2022-05-23 어플라이드 몰레큘라 트랜스포트 인크. 조성물, 제형, 및 인터루킨 제조 및 정제
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
JP2023517595A (ja) 2020-03-11 2023-04-26 アンブルックス，インコーポレイテッド インターロイキン－２ポリペプチド結合物およびその使用方法
CN116419747A (zh) 2020-08-07 2023-07-11 福蒂斯治疗公司 靶向cd46的免疫偶联物及其使用方法
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
FR2466252A2 (fr) * 1979-10-03 1981-04-10 Clin Midy Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine

Also Published As

Publication number Publication date
US4414148A (en) 1983-11-08
IL65441A0 (en) 1982-07-30
JPS57179124A (en) 1982-11-04
AU8251082A (en) 1983-04-21
SU1329604A3 (ru) 1987-08-07
EG15718A (en) 1986-09-30
DK159277B (da) 1990-09-24
DK167482A (da) 1982-10-16
FR2504010A1 (fr) 1982-10-22
PT74741B (fr) 1983-11-09
EP0063988A1 (fr) 1982-11-03
EP0063988B1 (fr) 1986-01-29
IE53009B1 (en) 1988-05-11
FI821304L (fi) 1982-10-16
FI76693B (fi) 1988-08-31
PH20846A (en) 1987-05-08
KR830009777A (ko) 1983-12-23
ES8303918A1 (es) 1983-02-16
FI76693C (fi) 1988-12-12
NO154905C (no) 1987-01-14
DK159277C (da) 1991-02-18
ES511433A0 (es) 1983-02-16
FR2504010B1 (fr) 1985-10-25
NO154905B (no) 1986-10-06
PT74741A (fr) 1982-05-01
CZ256482A3 (en) 1994-01-19
GR69199B (es) 1982-05-06
YU83082A (en) 1985-03-20
KR880001045B1 (ko) 1988-06-18
DD204849A5 (de) 1983-12-14
IE820815L (en) 1982-10-15
HU188314B (en) 1986-04-28
AU556641B2 (en) 1986-11-13
MA19429A1 (fr) 1982-12-31
CA1195248A (en) 1985-10-15
FI821304A0 (fi) 1982-04-14
PL135800B1 (en) 1985-12-31
ZA822528B (en) 1983-02-23
PL235981A1 (es) 1982-10-25
NO821198L (no) 1982-10-18
NZ200302A (en) 1985-03-20
AR228394A1 (es) 1983-02-28
ATE17653T1 (de) 1986-02-15
DE3268752D1 (en) 1986-03-13

Similar Documents

Publication Publication Date Title
OA07069A (fr) Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation.
OA07103A (fr) Nouvelles 1,2-diaminocyclobutène-3,4-diones, leur procédé de préparation et composition pharmaceutique les contenant.
DZ312A1 (fr) Interferons et procédé pour leur préparation.
IT1150682B (it) Procedimento per la produzione di sostanze prodotte da cellule,particolarmente di anticorpi e simili
FR2516794B1 (fr) Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d&#39;un anticorps monoclonal specifique
FR2552222B1 (fr) Ensemble d&#39;accelerometres pour plate-forme inertielle et plate-forme inertielle le comportant
FI822964L (fi) Med laosanordning foersedd icke-metallisk biologiskt anpassbar blodkaerlsklaemma
FR2344839A1 (fr) Composition, detecteur et methode pour la recherche d&#39;un composant dans un echantillon
OA05638A (fr) Nouveaux agents anthelminthiques et procédés pour leur préparation.
MC1418A1 (fr) 2,4-diamino-pyrimidines,leur preparation et medicaments contenant ces substances
FR2500166B1 (fr) Reactif et procede pour dosage immunologique d&#39;antigenes
OA08444A (fr) Nouveaux céphèmes et procédés pour leur préparation.
OA07172A (fr) Nouvelles thiazolidinediones, leur procédé de production et préparation pharmaceutique les contenant.
IT8719086A0 (it) Immunoglobulina iniettabile per via endovenosa con un elevato titolo di anticorpi contro il virussinciziale respiratorio, procedimento per la sua produzione e preparato farmaceutico che lo contiene.
OA05575A (fr) Nouveaux dérivés d&#39;indolizine, leur procédé de préparation ainsi que les compositions les contenant.
OA09190A (fr) &#34;Procédés de préparation de dérivés d&#39;acides benzocycloalcényl dihydroxy alcanoïques et de médicaments les contenant&#34;.
FR2527928B1 (fr) Procede de preparation d&#39;anticorps monoclonaux conjugues avec un chelate metallique et solution les contenant
OA07341A (fr) Nouveaux oximéthers, procédé pour leur préparation, agents contenant les nouveaux oximéthers et leur application.
IL77990A (en) Monoclonal anti-alpha-amylase antibody,process for obtaining the same and pharmaceutical compositions containing the same
FR2503713B1 (fr) 2,3-di-substitue-5,6-dihydro-imidazo-(2,1-b) thiazoles, procede pour leur preparation et agents anti-inflammatoires les contenant
NL186860C (nl) N,n&#39;-bis-(3-picolyl)-4-methoxy-isoftalamidemonohydraat, werkwijze voor de bereiding daarvan en farmaceutische preparaten, die dit bevatten.
FR2405731B1 (fr) Colonne de distillation a cloches a bulles d&#39;entretien facile, pour distillation de liquides encrassants et/ou a forts depots
PT77767B (fr) Procede de preparation de 3&#39;,5&#39;-diarabinosides et de compositi-ons pharmaceutiques les contenant
OA04266A (fr) Procédé et dispositif pour la préparation de pâtes carbonées, destinées à la fabrication d&#39;électrodes.
OA07256A (fr) Halaolkyl-8-4H-(1)-benzopyran-4-ones,et procédés de préparation.